Saltar al contenido
Merck

Opioids enhance CXCL1 expression and function after incision in mice.

The journal of pain : official journal of the American Pain Society (2014-06-03)
Yuan Sun, Peyman Sahbaie, DeYong Liang, Wenwu Li, J David Clark
RESUMEN

Chronic opioid consumption increases postoperative pain. Epigenetic changes related to chronic opioid use and surgical incision may be partially responsible for this enhancement. The CXCL1/CXCR2 signaling pathway, implicated in several pain models, is known to be epigenetically regulated via histone acetylation. The current study was designed to investigate the role of CXCL1/CXCR2 signaling in opioid-enhanced incisional sensitization and to elucidate the possible epigenetic mechanism underlying CXCL1/CXCR2 pathway-mediated regulation of nociceptive sensitization in mice. Chronic morphine treatment generated mechanical and thermal nociceptive sensitization and also significantly exacerbated incision-induced mechanical allodynia. Peripheral but not central messenger RNA levels of CXCL1 and CXCR2 were increased after incision. The source of peripheral CXCL1 appeared to be wound area neutrophils. Histone H3 subunit acetylated at the lysine 9 position (AcH3K9) was increased in infiltrating dermal neutrophils after incision and was further increased in mice with chronic morphine treatment. The association of AcH3K9 with the promoter region of CXCL1 was enhanced in mice after chronic morphine treatment. The increase in CXCL1 near wounds caused by chronic morphine pretreatment was mimicked by pharmacologic inhibition of histone deacetylation. Finally, local injection of CXCL1 induced mechanical sensitivity in naive mice, whereas blocking CXCR2 reversed mechanical hypersensitivity after hind paw incision. Peripheral CXCL1/CXCR2 signaling helps to control nociceptive sensitization after incision, and epigenetic regulation of CXCL1 expression explains in part opioid-enhanced incisional allodynia in mice. These results suggest that targeting CXCL1/CXCR2 signaling may be useful in treating nociceptive sensitization, particularly for postoperative pain in chronic opioid-consuming patients.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Dimetilsulfóxido, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Dimetilsulfóxido, ACS reagent, ≥99.9%
Sigma-Aldrich
Dimetilsulfóxido, for molecular biology
Sigma-Aldrich
Dimetilsulfóxido, suitable for HPLC, ≥99.7%
Sigma-Aldrich
Dimetilsulfóxido, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Dimetilsulfóxido, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Dimetilsulfóxido, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
Formaldehído solution, for molecular biology, 36.5-38% in H2O
SAFC
Formaldehído solution, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
Dimetilsulfóxido, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Formaldehído solution, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
Formaldehído solution, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
Dimetilsulfóxido, PCR Reagent
Sigma-Aldrich
SAHA, ≥98% (HPLC)
Supelco
Formaldehído solution, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
Formaldehído solution, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
Dimetilsulfóxido, meets EP testing specifications, meets USP testing specifications
USP
Dimetilsulfóxido, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Formaldehído solution, tested according to Ph. Eur.
Supelco
Dimetilsulfóxido, analytical standard
Supelco
Dimetilsulfóxido, for inorganic trace analysis, ≥99.99995% (metals basis)
Sigma-Aldrich
Formaldehyde-12C solution, 20% in H2O, 99.9 atom % 12C
Dimetilsulfóxido, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
GRO/KC from mouse, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)